Zhang Wen, Zhang Jing, Liang Xijun, Ding Jin
Clinical Cancer Institute, Center for Translational Medicine, Naval Medical University, 800 Xiangyin Road, 200433, Shanghai, China.
Department of Pathology, Changzheng Hospital, Naval Medical University, 415 Fengyang Road, 200003, Shanghai, China.
Cell Oncol (Dordr). 2023 Feb;46(1):1-15. doi: 10.1007/s13402-022-00732-2. Epub 2022 Nov 1.
As a malignant tumor, pancreatic cancer has an extremely low overall 5-year survival rate. Pancreatic adenosquamous carcinoma (PASC), a rare pancreatic malignancy, owns clinical presentation similar to pancreatic ductal adenocarcinoma (PDAC), which is the most prevalent pancreatic cancer subtype. PASC is generally defined as a pancreatic tumor consisting mainly of adenocarcinoma tissue and squamous carcinoma tissue. Compared with PDAC, PASC has a higher metastatic potential and worse prognosis, and lacks of effective treatment options to date. However, the pathogenesis and treatment of PASC are not yet clear and are accompanied with difficulties.
The present paper systematically summarizes the possible pathogenesis, diagnosis methods, and further suggests potential new treatment directions through reviewing research results of PASC, including the clinical manifestations, pathological manifestation, the original hypothesis of squamous carcinoma and the potential regulatory mechanism. In short, the present paper provides a systematic review of the research progress and new ideas for the development mechanism and treatment of PASC.
胰腺癌作为一种恶性肿瘤,其总体5年生存率极低。胰腺腺鳞癌(PASC)是一种罕见的胰腺恶性肿瘤,临床表现与最常见的胰腺癌亚型胰腺导管腺癌(PDAC)相似。PASC通常被定义为主要由腺癌组织和鳞癌组织组成的胰腺肿瘤。与PDAC相比,PASC具有更高的转移潜能和更差的预后,且迄今为止缺乏有效的治疗方案。然而,PASC的发病机制和治疗方法尚不清楚,且存在诸多困难。
本文通过回顾PASC的研究成果,包括临床表现、病理表现、鳞癌的起源假说及潜在调控机制,系统总结了其可能的发病机制、诊断方法,并进一步提出了潜在的新治疗方向。简而言之,本文对PASC的研究进展进行了系统综述,并为其发病机制及治疗提供了新思路。